Expertise in
12
conditions

Dr. Gretchen Glaser

Oncology
Mayo Clinic-Rochester
5716 Cleveland St Ste 200, 
Virginia Beach, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
12
conditions
Mayo Clinic-Rochester
5716 Cleveland St Ste 200, 
Virginia Beach, VA 

Overview

Gretchen Glaser is an Oncologist in Virginia Beach, Virginia. Dr. Glaser is highly rated in 12 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Lymphadenectomy.

Her clinical research consists of co-authoring 103 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in PA

Hospital Affiliations

Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Mayo Clinic-Rochester
5716 Cleveland St Ste 200, Virginia Beach, VA 23462
Other Locations
Mayo Clinic Hospital-Methodist Campus
201 Center St W, Rochester, MN 55902

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

103 Total Publications

ESGO-ESTRO-ESP guidelines 2025 vs 2021: reclassifying risk.
ESGO-ESTRO-ESP guidelines 2025 vs 2021: reclassifying risk.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: November 07, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Grace Dy
Oncology
Expertise in
15
conditions
Dr. Grace Dy
Oncology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Grace Dy is an Oncologist in Virginia Beach, Virginia. Dr. Dy is highly rated in 15 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Lymphadenectomy.

Expertise in
37
conditions
Dr. Ryan Law
Oncology
Expertise in
37
conditions
Dr. Ryan Law
Oncology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Ryan Law is an Oncologist in Virginia Beach, Virginia. Dr. Law is highly rated in 37 conditions, according to our data. His top areas of expertise are Bile Duct Obstruction, Cholestasis, Hereditary Pancreatitis, Endoscopy, and Gastric Bypass.

Expertise in
14
conditions
Dr. Joleen Hubbard
Oncology
Expertise in
14
conditions
Dr. Joleen Hubbard
Oncology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joleen Hubbard is an Oncologist in Virginia Beach, Virginia. Dr. Hubbard is highly rated in 14 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Hepato-Pancreato-Biliary Surgery.

Frequently Asked Questions about Dr. Gretchen Glaser

How do I make an appointment with Dr. Gretchen Glaser?

You can book an appointment with Dr. Gretchen Glaser by calling their office at 507-284-2511. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gretchen Glaser a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gretchen Glaser is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gretchen Glaser specialize in?

While Dr. Gretchen Glaser is a Oncology, they have specific expertise in Endometrial Cancer, Hysterectomy, and Ovarian Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Gretchen Glaser participate in research or clinical trials?

Yes. Dr. Gretchen Glaser has published 103 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Gretchen Glaser's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gretchen Glaser accept my insurance?

Dr. Gretchen Glaser accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 507-284-2511 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Glaser's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile